To elucidate mechanisms related to remission in winter seasonal affective disorder (SAD), we explored the course of individual depressive symptom offset across two distinct treatment modalities that show comparable outcomes at treatment endpoint: cognitive-behavioral therapy for SAD (CBT-SAD) and light therapy (LT).
. For example, Iacoviello, Alloy, Abramson, Choi, and Morgan (2013) found that the patterns of onsets and offsets of individual symptoms of hopelessness depression were consistent with those proposed by the theory of a hopelessness depression subtype.
For SAD, the observation of different temporal patterns of onset for different types of symptoms (Young, Watel, Lahmeyer, & Eastman, 1991) led to the dual vulnerability model of SAD in which psychological responses to environmentally triggered vegetative symptoms (e.g., sleep disturbance, fatigue, appetite changes) lead to the cognitive and affective symptoms that, in combination, constitute the full depressive syndrome. Tests of the dual vulnerability model have been supportive (e.g., Enggasser & Young, 2007; Whitcomb-Smith et al., 2014) .
However, the offset of symptoms in SAD has not yet been studied. SAD offset in response to treatment is particularly interesting because empirically supported treatments for SAD, at least in theory, may have different mechanisms. Bright light therapy (LT) has a long history of supportive research (see meta-analyses by Golden et al., 2005; Mårtensson, Pettersson, Berglund, & Ekselius, 2015) . LT's presumed therapeutic mechanism is through alterations in circadian rhythms (Lewy, Sack, Singer, & White, 1987) , although effects in the retina (Roecklein et al., 2013 ) may also play a role. More recently, trials comparing cognitive-behavioral therapy tailored to SAD (CBT-SAD) to LT found no differences between the two in depression improvements or remission rates at posttreatment (Rohan et al., 2007; Rohan et al., 2015) . For example, in the parent trial, posttreatment remission rates were 47.6% in CBT-SAD and 47.2% in LT (Rohan et al., 2015) . CBT-SAD includes behavioral activation aimed at decreasing avoidance and increasing engagement in pleasurable activities during the winter and cognitive therapy aimed at restructuring depressive thoughts, including SAD-specific negative cognitions about the seasons, light availability, and weather (Rohan, 2008 ; LT and CBT-SAD as employed in this study are described in detail in the Methods section). CBT-SAD's presumed antidepressant mechanism is through offsetting an underlying cognitive vulnerability to depression (Rohan, Roecklein, & Haaga, 2009 ). Although CBT-SAD and LT are very different treatments in terms of protocol and theoretical basis that lead to similar overall acute treatment responses, they could lead to different time courses of individual symptoms across the period of treatment. Thus, there could be different mechanisms and pathways to the same therapeutic end.
The present study examined the remission of individual symptoms in SAD across 6 weeks of a parent randomized clinical trial and, in particular, compared the time to remission of each symptom between participants receiving LT and those receiving CBT-SAD. Survival analysis was used to provide information about the distribution of remissions across the weeks of treatment and the risk (hazard) of remission in each week among those for whom the symptom had not yet remitted.
Comparison of these results between treatments provides information about the differential longitudinal therapeutic effects of LT and CBT-SAD on the symptom level, as well as clues about the nature of the therapeutic mechanisms underlying the two treatments.
We have chosen not to make specific hypotheses about differential time courses of symptom remission according to the treatment received. There is very little theoretical or empirical literature on patterns of remission by symptom. Some ideas have been put forward that early onset core symptoms would be among the first, or among the last, to remit (see Iacoviello et al., 2010, p. 460) . However, of greatest concern is that no work on this issue has considered whether remissions are spontaneous or treatment-induced, and, if treatmentinduced, whether different treatments might induce different time courses in the remissions of particular symptoms. Given this situation, there was little basis for making a priori hypotheses and we took an exploratory approach.
MATERIALS AND METHODS

Participants
This study constitutes a secondary analysis of data collected from a randomized clinical trial (RCT) comparing the efficacy of two distinct treatments for seasonal affective disorder (SAD; Rohan et al., 2013 Rohan et al., , 2015 . All participants provided informed consent prior to enrolling in the parent RCT. The study was conducted at the University of Vermont and was approved by the institutional review board. As part of the parent RCT, participants were randomized to 6 weeks of cognitive-behavioral therapy for SAD (CBT-SAD) or light therapy (LT).
Participants, aged 18 years or older, were recruited from the greater Burlington, VT region. Inclusion criteria consisted of (a) meeting (First, Spitzer, Gibbon, & Williams, 1995) and (b) symptom severity criteria of a total score of at least 20 on the Structured Interview Guide for the Hamilton Rating Scale for Depression-Seasonal Affective Disorder Version (SIGH-SAD: Williams, Link, Rosenthal, Amira, & Terman, 1992) , with a minimum of 5 on the atypical scale and a minimum of 10 on the remaining items. Individuals were ineligible to participate if they (a) were receiving or planned to receive either LT or psychotherapy for depression during the same winter they intended to enroll, (b) had a history of LT or CBT-SAD, (c) had any comorbid Axis I disorder requiring immediate treatment, (d) had hypothyroidism (assessed via thyroid panel), (e) had travel arrangements through the beginning of spring (March), or (f) had suicidal ideation that would contraindicate participation.
For each symptom examined, the sample for the survival analysis included (1) those participants who exhibited the symptom at pretreatment and (2) those participants who had no more than 3 weeks of missing data (see Missing Data Handling below). Applying those criteria, total sample size here was 163 (76 CBT-SAD, 87 LT). However, sample sizes for analyses of individual symptoms were smaller and varied since each symptom needed to be present at baseline to be included in the analysis (see Table 1 ). Most participants were female (84.0%) and non-Hispanic white (92.6%). Participants' mean (SD) age was 45.4 (12.7) years. For detailed demographic information and baseline characteristics from the parent RCT, see Rohan et al., 2015 . 
TA B L E 1 Sample flow chart
CBT-SAD LT
Treatments
CBT-SAD (Rohan, 2008 ) is a group therapy intervention consisting of 12 90-min sessions (two sessions per week) over the course of 6 weeks.
CBT-SAD incorporates traditional components of CBT (e.g., behavioral activation, cognitive restructuring, and relapse-prevention planning)
to promote effective coping with the winter season. In addition to targeting typical depressogenic thoughts, some cognitive restructuring in CBT-SAD centers on negative automatic thoughts about winter, reduced photoperiods, and cold and snowy weather conditions. Behavioral activation in CBT-SAD seeks to identify and increase pleasant activities that can be done in the winter to increase pleasure and mas- CBT-SAD participants attended most sessions (M = 9.1, SD = 3.5).
Of 13 CBT-SAD participants who withdrew, seven did not attend any sessions and six attended a minimum of two and a maximum of seven sessions. LT adherence was monitored using LT diaries (Rohan et al., 2015) .
Measures
Structured interview guide for the Hamilton Rating Scale for Depression-Seasonal Affective Disorder version (SIGH-SAD)
The SIGH-SAD is a 29-item clinical interview that expands the 21-item Hamilton Rating Scale for Depression (HAM-D) to include eight items assessing "atypical symptoms" of depression that are common in SAD. Total SIGH-SAD scores can range from 0 to 90. Symptom severity was assessed via blind interviewer at pre-treatment, weekly during treatment (treatment weeks 1-5) and upon completing treatment (posttreatment). Rater's made scoring decisions based on clearly defined item scoring rules . In the parent trial, episode remission was defined as a pre-to posttreatment total SIGH-SAD score reduction of at least 50% in addition to a 21-item HAM-D score ≤ 7 and an eight-item atypical score ≤ 7. Episode remission status also could be obtained by a 21-item HAM-D score ≤ 2 and an eight-item atypical score ≤ 10. All SIGH-SAD interviews were audio recorded and independently rated by a second blinded rater. Discrepancies between raters were resolved using the procedures outlined in . Intraclass correlations for inter-rater reliability ranged between 0.92 and 0.97 for pre-treatment, treatment weeks 1-5, and posttreatment (see .
Symptom remission
In the present study, our outcome of interest was the time to sustained remission of each individual symptom (i.e., SIGH-SAD item) during the 6-weeks treatment phase. For a symptom to be included in these secondary analyses, 41 or more participants had to exhibit the symptom at pretreatment. Any symptom endorsed by 40 or fewer participants was not examined because it was judged to be insufficiently common to allow reliable estimates in a survival analysis. Based on this criterion, 17 of the 29 SIGH-SAD symptoms were studied (Table 1) . A symptom was considered remitted if the score of the corresponding SIGH-SAD item was zero at a particular week during treatment (remission week) and the symptom remained at zero through the end of treatment. For example, [2, 2, 0, 0, 0, 0] would be a remission at week 3, [2, 2, 0, 1, 0, 0] would be a remission at week 5, and [2, 2, 0, 1, 0, 1] would be failure to reach remission. For the purpose of this study and the survival analyses, we were only concerned with whether a symptom was absent (0) or present (> 0) each week. Therefore, following the handling of missing data, all symptom severities greater than zero were recoded to one.
Missing data handling
Missing data were considered separately for each symptom and each participant. Only cases that had three or fewer missed weeks were included in the survival analysis sample. In cases where a participant was missing data from one or more time points that were preceded and followed by data being present, we imputed the missing values by using the mean of the participant's immediately preceding and succeeding non-missing values (Engels, 2003) . For example, if a participant's symptom severity data was [2, 2, 0, _, 1, 0], the missing value would be equal to 0.5 (the mean of the preceding 0 and subsequent 1). Means < 0.5 were recoded as 0 (symptom absent); means ≥ 0.5 were recoded as 1 (symptom present).
For cases with data at the final (post-treatment) timepoint, but with data missing in the immediately preceding two or three consecutive time points, the last preceding observation was carried forward. For example, for the data [2, 2, 1, _, _, 0], the missing values were replaced with 1s (Engels, 2003) . Cases with data missing at the final, posttreatment timepoint were considered as right censored at the last timepoint at which there was data present. For example, [2, 1, 2, 3, _, _) was considered censored at week 4. As noted above, following these procedures all symptom scores consisted of either 0s (absent), 1s (present), or missing through the end of the trial.
Data analyses
Data pre-processing, statistical analyses and visualizations were completed using R version 3.2.3 (R Core Team, 2015) with the following packages: plyr (Wickham, 2011) , dplyr (Wickham & Francois, 2015) , ggfortify (Horikoshi & Tang, 2015) , ggplot2 (Wickham, 2009 ), zoo (Zeileis & Grothendieck, 2005) , and survival (Therneau, 2015) . All ttests and repeated measures ANOVAs were completed using SPSS v.24 (IBM Corp., 2016). Independent samples t-tests were conducted to assess differences in symptom severity at pretreatment. Mixed repeated measures analysis of variance (ANOVA) was used to assess treatment group differences in changes in symptoms severity.
Survival analyses were conducted to assess the time to symptom remission for each treatment condition (Singer & Willett, 2003) .
Because SIGH-SAD data were collected each treatment week, weeks were the unit of time. Participants who did not experience remission during the 6-week study period were considered censored since they may not have been observed long enough to capture a remission. Our survival analyses yielded Kaplan-Meier survival probability estimates, which show the distribution of remissions over time as a proportion of the total sample. In this application, survival indicates "survival of the symptom," such that the lower the survival probability, the greater the rate of remission. Differences between CBT-SAD and LT Kaplan-Meier survival probability estimates for each symptom were tested using a log-rank test, which compares the survival functions as whole. Hazard rates are the probabilities of remitting in a time period in those not having the symptom at the beginning of the period (i.e.
, not yet remitted). Thus, hazards represent the "pressure to remit" at a given point in time. Both survival and hazard functions were examined graphically to determine which symptoms had the most similar and most divergent patterns of remission between CBT-SAD and LT.
Results
2.7.1
Treatment group differences in overall symptom severity change Time (pre-, posttreatment) by treatment (CBT-SAD, LT) mixed ANOVAs for each symptom (Table 2 ) resulted in only one marginally significant interaction effect (anxiety-somatic, p = .05) However, the groups' mean scores on this symptom did not differ significantly at posttreatment (CBT-SAD: M = .66; LT: M = .76; SE = .16, Fisher Least Significant Difference, ns). Thus, the absence of significant time and treatment group effects suggests that pre-, post-treatment changes in the severity of each symptom were similar in the two treatment conditions. Furthermore, for every symptom, there was a significant main effect of time, indicating that, across both treatments, symptom severity decreased over the 6 weeks.
Given the results above, we also examined whether the severity of each symptom at pretreatment differed by treatment, corroborating the effectiveness of the random assignment. Independent samples ttests (Table 3 ) revealed only two symptoms that differed significantly by treatment group at pretreatment, feelings of guilt (with LT > CBT-SAD) and anxiety-somatic (with CBT-SAD > LT). Thus, the two treatment groups started the study with comparable severities on nearly all the symptoms studied.
Time to symptom remission
Survival analyses provided patterns across treatment weeks of (a) survival, i.e., the probability of the symptom continuing unremitted ("surviving") and (b) hazards, i.e., the probability of remitting among those individuals who had not yet remitted. Figures 1-4 show the survival and hazard graphs for eight representative symptoms. Survival functions (Figures 1 and 3) indicated that, regardless of treatment modality, the likelihood of remission for each of the 17 symptoms steadily increased as treatment progressed. This pattern is unsurprising given that both treatments resulted in significant and comparable episode remission rates and changes in overall symptom severity (see Rohan et al., 2015) . The hazard functions of each of the 17 symptoms (Figures 2 and 4) most frequently increased over time, suggesting that the pressure for each symptom to remit generally increased over time.
TA B L E 2 Main and interaction effects from repeated measures ANOVA
TA B L E 3 Results of independent samples t-test at pretreatment
Symptom
CBT-SAD M (SD)
However, in the sixth and last week of treatment risk of remission was particularly elevated in both treatment groups. This suggests that for both LT and CBT-SAD, there may be particular mechanisms contributing to symptom remission later on in treatment and, therefore, particular benefits of completing the entire course of treatment.
Of the 17 symptoms studied, 13 failed to show a statistically significant difference between CBT-SAD and LT in the pattern of estimates are often (as here) more variable than survival estimates because they depend in part on the number of participants remaining at risk in each time period (Singer & Willett, 2003, p. 349 ). In addition, as noted earlier, the final treatment week may include special remission processes for both groups, and so hazard function patterns might most clearly be interpreted from weeks 1 through 5. It also is useful to remember in discerning patterns that the points in the hazard graphs are empirical values that include "error" around an underlying pattern-like the scatter of points around a regression line.
TA B L E 4
Log-rank test results between groups for estimated survival curves Overall, for all four symptoms at all weeks, the risk of remission was nearly always either close to equal or, more often, greater for LT compared to CBT-SAD. These higher risks of remission in LT contribute to the more rapid remissions seen in survival functions (Figure 3 ). For early insomnia and psychic anxiety, LT showed a generally increasing pressure to remit across time not seen with CBT-SAD. For hypersomnia, the pressure to remit is constant for both treatments, but greater for LT. For social withdrawal, the patterns for the two treatments were also parallel, constant over the first 3 weeks and increasing thereafter, with the pressure to remit greater for LT.
DISCUSSION
For the large majority of symptoms included in this study (13/17; 76%), time to remission did not differ based on whether participants received CBT-SAD or LT. The fact that most the symptoms remitted comparably across time in the two treatments may account for the overall comparable episode remission rates (47.6% in CBT-SAD and 47.2% in LT), which were based on SIGH-SAD total scores (Rohan et al., 2015) . On an individual symptom level, most depressive symptoms, typical and atypical, remitted comparably in treatments that presumably operate on distinct mechanisms. This finding is consistent with that of Stassen et al. (1993) , who found using survival analysis that the time course of improvement in depression was no different between patients who responded to antidepressant medication and those who responded to placebo. Following the interpretation of those authors, it may be that there are common recovery mechanisms in SAD that can be triggered by either LT or CBT-SAD and that once those recovery mechanisms are triggered the course of recovery is essentially the same regardless of the treatment modality.
However, for four symptoms, LT led to more rapid remission than did CBT-SAD: early insomnia, hypersomnia, psychic anxiety, and social withdrawal. The observation that LT led to faster remission of two sleep symptoms is consistent with sleep having a circadian regulation component (Cirelli, 2009 ) and with the theory that SAD is related to a pathological circadian phase-shift that can be corrected with LT (Lewy et al., 2006; Lewy, Sack, Miller et al., 1987) . Earlier remission of insomnia and hypersomnia with LT suggests that those in CBT-SAD with these particular symptoms may benefit from a supplementary course of chronobiological treatment in order to remit these particular symptoms more quickly. CBT-SAD is hypothesized to improve SAD by modifying psychological phenomena such as dysfunctional attitudes, maladaptive seasonal beliefs, rumination, and low response-contingent positive reinforcement in the winter, which are correlates of SAD (Hodges & Marks, 1998; Levitan et al., 1998; Rohan et al., 2003; Young & Azam, 2003) . Given its focus on maladaptive cognitions and pleasurable activities, CBT-SAD may take longer than LT to reduce particular symptoms, like hypersomnia and early insomnia.
Why remission of social withdrawal and psychic anxiety would be faster with LT is less clear. Unfortunately, the SIGH-SAD does not contain any items that appear to capture negative cognitive styles (i.e., a tendency toward negative inferences and dysfunctional attitudes; see Alloy et al., 2000) , which might be better candidates for earlier remis- efficacy results in the parent study (Rohan et al., 2015) highlight that regardless of the assumed mechanism of action, cognitive or chronobiological, the substantial majority of symptoms, and overall symptom severity are comparably reduced across 6-weeks of CBT-SAD and LT.
To the treating clinician, the practical implication is that, overall, both treatments end up in the same place after 6 weeks of treatment, but the time course to arrive there is faster in LT than in CBT-SAD for certain symptoms.
This study has several limitations. One issue is the decision to study complete remission of a symptom, as opposed to substantial improvement or the trajectory of decreasing symptom severity. In addition to remission being of interest, this decision was based on the fact that Several symptoms were not studied in the current secondary analyses because 40 or fewer participants endorsed them at pretreatment.
Among these excluded SIGH-SAD symptoms were weight loss, late insomnia, somatic symptoms, suicidal thoughts, psychomotor retardation, psychomotor agitation, depersonalization/derealization, paranoia, and obsessive/compulsive behaviors. Although these symptoms are less common and not considered core symptoms of SAD, understanding the course of less frequent symptoms may provide insights for clinicians who are working with patients with significant comorbidities or unusual SAD presentations.
In the parent trial, CBT-SAD had more durable effects than LT at follow-up two winters later . Specifically, CBT-SAD participants had fewer depression recurrences (27.3% vs. 45.6%) two winters following treatment, less severe symptoms on the SIGH-SAD as well as the Beck Depression Inventory-Second Edition (BDI-II; Beck, Steer, & Brown, 1996) , and a larger proportion of remissions defined by BDI-II ≤ 8 (68.3% vs. 44.5%) than LT participants. This study's focus on the patterns of acute remission of individual SAD symptoms across theoretically distinct treatments reveals that while CBT-SAD has comparable treatment effects to LT at the episode level during acute treatment, and has clear prophylactic advantages over LT across time, for certain symptoms, CBT-SAD may operate more slowly than LT. This initial examination of the specific symptom-level data highlights that regardless of the underlying chronobiological or psychological mechanism of a particular SAD symptom, the psychological and chronobiological mechanisms may be more interrelated than previously thought.
Psychological treatments such as CBT-SAD can effectively treat symptoms that are largely considered to be chronobiological in nature if
given the proper amount of time for the treatment to take effect. Similarly, symptoms that might operate through psychological mechanisms can be effectively treated in the short term through chronobiological treatments. Future work examining the specific cognitive and chronobiological mechanisms of change leading to symptom-level remission is warranted.
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